Ewa Karwatowska-Prokopczuk

Ewa Karwatowska-Prokopczuk

Auto-generated profile, based on publicly available information

Ewa Karwatowska-Prokopczuk

Akcea Therapeutics , 55 Cambridge Parkway Suite 100 Cambridge, Boston, MA 02142, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Jean-Claude TardifJean-Claude Tardif
Jean-Claude Tardif
EKEwa Karwatowska-Prokopczuk
Ewa Karwatowska-Prokopczuk
EAEric St Amour
Eric St Amour
CBChristie M Ballantyne
Christie M Ballantyne
MSMichael D Shapiro
Michael D Shapiro
DGDaniel Gaudet
Daniel Gaudet
Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease. A randomized, double-blind, placebo-controlled, dose-ranging study was conducted in 114 patients with fasting serum triglycerides 200–500 mg/dL (2.26–5.65 mmol/L). Patients received olezarsen (10 or 50 mg every 4 weeks, 15 mg every 2 weeks, or 10 mg every week) or saline placebo subcutaneously for 6–12 months. The primary endpoint was the percent change in fasting triglyceride levels from baseline to Month 6 of exposure. Baseline median (interquartile range) fasting triglyceride levels were 262 (222–329) mg/dL [2.96 (2.51–3.71) mmol/L]. Treatment with olezarsen resulted in mean percent triglyceride reductions of 23% with 10 mg every 4 weeks, 56% with 15 mg every 2 weeks, 60% with 10 mg every week, and 60% with 50 mg every 4 weeks, compared with increase by 6% for the pooled placebo group (P-values ranged from 0.0042 to 10.0 mmol/L primarily pancreatitis risk in patients with familial chylomicronemia syndrome and multifactorial chylomicronemia syndrome (represented by milky plasma). Treatment with olezarsen with the planned Phase 3 doses of 50 and 80 mg subcutaneously monthly would be expected to substantially reduce triglyceride levels in the entire continuum of hypertriglyceridaemia.


3 November 2009 in Circulation
Verified
Journal Article
Closed access
JHJames R Harkness
James R Harkness
DMDavid A Morrow
David A Morrow
EBEugene Braunwald
Eugene Braunwald
JQJie Qin
Jie Qin
LBLuiz Belardinelli
Luiz Belardinelli
BSBenjamin M Scirica
Benjamin M Scirica